Potential Causes of Higher Mortality in Elderly Users of Conventional and Atypical Antipsychotic Medications

Authors

  • Soko Setoguchi MD, DrPH,

    1. From the *Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, and Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
    Search for more papers by this author
  • Philip S. Wang MD, DrPH,

    1. From the *Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, and Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
    Search for more papers by this author
  • M. Alan Brookhart PhD,

    1. From the *Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, and Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
    Search for more papers by this author
  • Claire F Canning MS,

    1. From the *Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, and Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
    Search for more papers by this author
  • Liljana Kaci BA,

    1. From the *Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, and Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
    Search for more papers by this author
  • Sebastian Schneeweiss MD, ScD

    1. From the *Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, and Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
    Search for more papers by this author

Address correspondence to Soko Setoguchi, MD, DrPH, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, 1620 Tremont Street, Suite 3030, Boston, MA 02120. E-mail: ssetoguchi@partners.org

Abstract

OBJECTIVES: To investigate the potential mechanisms through which conventional antipsychotic medication (APM) might act, the specific causes of death in elderly patients newly started on conventional APM were compared with those of patients taking atypical APM.

DESIGN: Cohort study.

SETTING: Community.

PARTICIPANTS: All British Columbia residents aged 65 and older who initiated a conventional or atypical APM between 1996 and 2004.

MEASUREMENTS: Cox proportional hazards models were used to compare risks of developing a specific cause of death within 180 days of APM initiation. Potential confounders were adjusted for using traditional multivariable, propensity-score, and instrumental-variable adjustments.

RESULTS: The study cohort included 12,882 initiators of conventional APM and 24,359 initiators of atypical APM. Of 3,821 total deaths within the first 180 day of use, cardiovascular (CV) deaths accounted for 49% of deaths. Initiators of conventional APM had a significantly higher adjusted risk of all CV death (hazard ratio (HR)=1.23, 95% confidence interval (CI)=1.10–1.36) and out-of-hospital CV death (HR=1.36, 95% CI=1.19–1.56) than initiators of atypical APM. Initiators of conventional APM also had a higher risk of death due to respiratory diseases, nervous system diseases, and other causes.

CONCLUSION: These data suggest that greater risk of CV deaths might explain approximately half of the excess mortality in initiators of conventional APM. The risk of death due to respiratory causes was also significantly higher in conventional APM use.

Ancillary